Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Decrease in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 14,500 shares, a decline of 68.0% from the March 31st total of 45,300 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily volume of 55,500 shares, the days-to-cover ratio is currently 0.3 days.

Alzamend Neuro Stock Performance

Shares of NASDAQ:ALZN traded up $0.02 during midday trading on Friday, reaching $0.72. 14,435 shares of the company’s stock traded hands, compared to its average volume of 46,123. Alzamend Neuro has a one year low of $0.65 and a one year high of $11.91. The company has a market cap of $4.94 million, a price-to-earnings ratio of -0.74 and a beta of 0.02. The stock has a 50 day moving average of $0.92 and a 200 day moving average of $1.23.

Alzamend Neuro (NASDAQ:ALZN) last posted its earnings results on Monday, March 25th. The company reported ($0.38) earnings per share (EPS) for the quarter.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.